A new preclinical study has demonstrated the treatment of RAS-mutant cancers with combined therapies targeting polyADP ribose polymerase (PARP) and mitogen-activated protein kinase (MEK) inhibitors.
Research has suggested that a signaling lymphocytic activation molecule contributes to differences in immunotherapy efficacy in hematopoietic tumors.
Researchers at the University of Michigan Health System (MI, USA) have identified a protein that assists ovarian cancer cells multiply and spread, providing a new target for therapy.
A new study may have identified a novel solution to treating lung cancer, through the use of a glycosylation inhibitor.
Retrospective analysis finds association between increased expression of metabolism-associated genes and lack of response to nivolumab in PD-L1- positive renal cell carcinoma.
Oncogenic gene fusions of neurotrophic tyrosine kinase genes have been identified in solid tumors and studies have shown them to be associated with worse survival in all types of lung cancer – is there any potential in inhibitors of these genes in the disease?
Researchers have identified a potential new class of personalized anticancer drugs that targets the Notch pathway in a proof-of-concept demonstration.
Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review
This case study from CNS Oncology reports a 37-year-old woman’s case with recurrent and rapidly progressive VHL-associated hemangioblastomas, causing severe disability.
Long-awaited results from a Phase III clinical trial have indicated that 10 years of hormone therapy reduces the risk of recurrence in breast cancer patients, without compromising quality of life.